Australia's largest stock trading and investment forum Australia's #1 stock forum

NXS

Click for more information

1.32%

37.5¢ next science limited

The story above makes the point that issues (if there are any )...

First 349 Last

Share
Profile

Follow
sabine

17,774 Posts.

3700

16/10/19

10:51

Post #: 40904696
Share

Originally posted by sabine ↑

Thank you Saragian .

From the image the price does seem to be ranging.
You are a genie of the highest order and that I am now (sometimes) making prudent choices is a breakthrough moment
Your commendation, perhaps bizarrely, had me smiling with genuine delight all afternoon .
I love your words.

I finally bought the new car this afternoon too, and expect I was also prudent there (a Forester fits in with the destined usage better than one with more glamour).
...That was a job I’m pleased to be on the other side of, although it will be exciting when it arrives.

And congratulations to your daughter on her dad and on her choice regards the one that has been sizzling.

You are wonderful.

From Stock Hed yesterday an interview with George Savvides where he makes the point NextScience has a range of products and is not tied to just one partner ....

Cheers

https://stock head.com.au/health/interview-next-science-chairman-george-savvides-on-whats-in-store-for-the-bacteria-killing-biotech/
“Interview: Next Science chairman George Savvides on what’s in store for the bacteria-killing biotech
23 hours ago | Sam Jacobs

After raising $35m at $1 a share, the stock ran hot to a high above $4.50 in mid-June, before easing back in the second half of the year.

But markets are keeping a close eye on the company’s US-focused distribution strategy centred around Xbio — a patented product which attacks the Biofilm that protects bacteria when it forms during surgery and wounds.

Wilsons analysts Elyse Shapiro and Shane Storey recently published some detailed research with a 12-month price target of $3.46 — a 31.5 per cent premium to yesterday’s closing share price.

Stock head recently caught up with George Savvides, Next Science’s non-executive Chairman, for a chat about the current outlook.

Savvides joined the company in July last year after a high-profile career in healthcare, including a 14-year stint as CEO of Medibank Private.

Among various takeaways, Savvides highlighted how his professional experience has helped inform his view about Next Science’s future application. The full transcript is outlined below:

Can you provide a brief overview of your career, and how that connects with what problems Next Science is trying to solve in the current market?

I think it all does connect in terms of the confidence I had in taking a governance role at NXS. I got into critical care and equipment fairly early in my career, then in 1999 I got my first exposure to a public board and the listing process with Sigma. I did five years there before I moved on to Medibank.

One of the key things I learnt at Medibank is how payers understand the health system. Because prior to that, I was a supplier and/or provider — we were always looking for someone to pay us.

But when you go to the other side as a payer, it sort of gives you a different view of the world. You start asking questions like — well how come one sixth of these surgeries have to be done a second time? And you find out one of the major causes is infection.

View attachment 1779944
Next Science non-executive chairman, George Savvides
Then you look into that and think — well what’s an appropriate level? We had a look at the data across all of our hospitals, and found there was a signifiant variation in infection.

Some hospitals were low and some were high, irrespective of age of the patient. So those healthcare practices came into the spotlight, once we understood that some hospitals were better at safety and infection management than others.

When considering the prevalence of infection, can you add some extra detail on how NXS is offering a unique solution to the market?

In the end, the problem with current practices is they don’t try and cure the cause, they manage the infection and keep it under control. But the bugs adapt and mutate, and build an effective “bomb shelter” around the infection called biofilm.

What NXS is doing is hitting that biofilm with a complex, aggressive and non-toxic formulation. The company has worked out a way to disentangle the shelter layer, pull it apart and attack the cause of the infection. So rather than wound management, it cures the actual cause.

I think the biggest piece of unfinished business in healthcare in the world today is infection. It’s not sexy, and has been around for 100+ years. But if you have a patient with an expensive surgery that gets infected — first they pay more to get the infection out, then they redo the first surgery with less bone to work with followed by a more complex rehab process.

In that situation the payers — whether it’s Medicare or private players such as Medibank — they’re perfectly aligned on this topic because they don’t want to pay twice, and no patient wants the surgery twice either.

Having made a strong start on the ASX, what’s the company’s strategic focus over the next 12 months?

In terms of deploying the funds ($35m) raised, nothing’s changed from what we outlined the prospectus. The aim is to accelerate the development of product delivery, and we thought the time was right to get some capital and turn it into a revenue story — that was the tipping point to move to a public float.

Few irons in the fire, because in the early going there’s nothing smooth about revenue growth, it’s always lumpy. It’s busy but it’s not diluted — that’s the way Matt [NXS founder and chief technical officer Dr Matthew Myntti] runs the lab. He ensures there’s a parallel runway to product development moving into adjacent markets.

The company has taken a portfolio approach to revenue creation by product breadth, but also in terms of market penetration. We’re not just going with one partner, we’ve multiple distribution pathways and a broad enough portfolio not to have to directly pursue one hospital network.

Are there many competitors in the space that might pose a threat to Next Science’s commercial aspirations?

There’re lots of competitors out there, but when you look at the application they manage infection by lowering the bug-rate — our product removes the bug-rate.

Biofilms have become an emerging conversation among scientists and researchers in healthcare. People are starting to understand that infection isn’t just the nature of the bug, it’s the shroud that covers the bug as well.

This product is genuine innovation — it’s not so much a smart molecule in terms of pharmaceuticals, its much more a material science approach and the gross margins are very attractive.

The biggest challenge for us is driving adoption by users, to start to implement a fundamental change in medical practice.

I’m really pleased with the board that we’ve put together, and a key part of our job as a governance board is to help foster those changes to the medical landscape.”

Expand

The story above makes the point that issues (if there are any ) due to the 3M partnership are contained.
There’s also mention of new developments, and the fact competitors’ products don’t tackle the issue of infection in the same way ...

These are comments that have already been comprehensively covered in the forum.
but the statement below is not something that has been much talked about?

“The biggest challenge for us is driving adoption by users, to start to implement a fundamental change in medical practice.”

... As I read it, George. Savvides is simply saying NextScience needs stronger marketing?

Implementing the fundamental change in medical practise he wants to achieve is not the kJ f of thing I expect traditionally comes about overnight - especially with hostile competitors protecting their interests.

....But in a world where things are constantly ‘going viral’ why take the traditional route?

Maybe for hospital-related sales it is necessary to operate through normal marketing channels - the trade shows etc but it sounds to me as if those arenas are controlled by the big entities, and the formula for successful selling is ‘who you know’ rather than what you can offer.

If NXS is is banging on the door of an essentially closed shop with the trade shows maybe it should be also using alternative marketing strategies on social media to inform the public direct ?

They are an incredibly professional team and no doubt already have this well in hand - ( they are possibly waiting on the launch of the acne products to start a campaign?), but currently I can’t even find the Facebook page nor an instagram account.

The Twitter page has a good update regards 3M actually doing some marketing (hopefully) for BlastX at a Las Vegas trade show that finished on Monday, but does not seem very oriented to marketing direct to the public.

Maybe I have the wrong end of the stick but I thought one of the best things about Blast X was that it’s like the perfect alternative to Dettol and to tree oil etc and you could put it on bandaids and possibly into soaps and supermarket trolley wipes and into aeroplanes and public toilets and everywhere else that ‘germ phobic’ civilised nations want to use it .....maybe even into mouthwash and toothpaste?

Cheers

Last edited by sabine: 16/10/19

NXS Price at posting: $2.76 Sentiment: None Disclosure: Held
3 Upvote

1 Great analysis

Reply

There are more pages in this discussion • 584 more messages in this thread...

First 349 Last

Add NXS (ASX) to my watchlist

(20min delay)
Last 37.5¢		Change -0.005(1.32%)		Mkt cap ! $109.3M

Open	High	Low	Value	Volume
38.5¢	38.5¢	37.5¢	$37.03K	97.17K

Buyers (Bids)

No.	Vol.	Price($)
1	10000	35.0¢

Sellers (Offers)

Price($)	Vol.	No.
38.5¢	33285	1

View Market Depth

No.	Vol.	Price($)
1	10000	0.350
1	14000	0.330
1	3076	0.325
1	62500	0.320
1	3175	0.315

Price($)	Vol.	No.
0.385	33285	1
0.390	55412	1
0.400	672	2
0.415	10000	1
0.420	28189	2

Last trade - 16.10pm 15/05/2024 (20 minute delay)


Last 37.5¢			Change -0.005 ( 0.00 %)
Open	High		Low	Volume
38.5¢	39.0¢		37.5¢	6130
Last updated 14.36pm 15/05/2024 ?

NXS (ASX) Chart

SPONSORED BY